Jay S. Duker - 09 Feb 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role: Chief Operating Officer
Signature: /s/ Ron Honig, Attorney-in-Fact
Issuer symbol: EYPT
Transactions as of: 09 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2022, 15:41:11 UTC
Previous filing: 03 Nov 2021
Next filing: 24 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EYPT	Common Stock	Options Exercise	$0	+4,966	+88%	$0.000000	10,623	09 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EYPT	Restricted Stock Units	Award	$0	+21,000		$0.000000	21,000	09 Feb 2022	Common Stock	21,000	$0.000000	Direct	F1
transaction	EYPT	Restricted Stock Units	Options Exercise	$0	-4,966	-33%	$0.000000	9,934	09 Feb 2022	Common Stock	4,966	$0.000000	Direct	F2
transaction	EYPT	Stock Option (Right to Buy)	Award	$0	+85,000		$0.000000	85,000	09 Feb 2022	Common Stock	85,000	$10.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F2	The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F3	The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.